Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

Rentian Feng, PhD, Gulsum Anderson, PhD, Guozhi Xiao, MD, PhD, Gary Elliott, PhD, Lorenzo M. Leoni, MD, Markus Y. Mapara, MD, PhD, David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 3456.

https://doi.org/10.1182/blood.V108.11.3456.3456

Published: 2006

Journal Articles

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth

Rentian Feng, Gülsüm Anderson, Guozhi Xiao, Gary Elliott, Lorenzo Leoni, Markus Y. Mapara, G. David Roodman, Suzanne Lentzsch

Blood (2006) 109 (5): 2130–2138.

https://doi.org/10.1182/blood-2006-07-027458

Published: 2006

Includes: Supplemental data

Journal Articles

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Hiroshi Yasui, Teru Hideshima, Makoto Hamasaki, Aldo M. Roccaro, Norihiko Shiraishi, Shaji Kumar, Pierfrancesco Tassone, Kenji Ishitsuka, Noopur Raje, Yu-Tzu Tai, Klaus Podar, Dharminder Chauhan, Lorenzo M. Leoni, Sarath Kanekal, Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 106 (2): 706–712.

https://doi.org/10.1182/blood-2005-02-0838

Published: 2005

Journal Articles

Mechanism of Action and Safety of Second Generation Analogs of SDX-101 (R-Etodolac).

Lorenzo M. Leoni, Ph.D., Brian Crain, Brandi Bailey, Mimi Phillips, Heather Bendall, Ph.D., Qi Chao, Ph.D., Jack Reifert, Christina Niemeyer, Ph.D., Gary Elliott, Ph.D.

Blood (2004) 104 (11): 3411.

https://doi.org/10.1182/blood.V104.11.3411.3411

Published: 2004

Journal Articles

SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.

Makoto Hamasaki, Teru Hideshima, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Shaji Kumar, Noopur Raje, Aldo M. Roccaro, Yu-Tzu Tai, Reshma Shiringarpure, Lorenzo Leoni, Sarath Kanekal, Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2004) 104 (11): 3466.

https://doi.org/10.1182/blood.V104.11.3466.3466

Published: 2004

Journal Articles

SDX-105 (Treanda™) Enhances the Tumor Growth Inhibitory Effect of Rituximab in Daudi Lymphoma Xenografts.

Sarath Kanekal, PhD, DABT, Brian Crain, Gary Elliott, PhD

Blood (2004) 104 (11): 4580.

https://doi.org/10.1182/blood.V104.11.4580.4580

Published: 2004

Journal Articles

Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production

Mee Rhan Kim, Raffi Manoukian, Richard Yeh, Scott M. Silbiger, Dimitry M. Danilenko, Sheila Scully, Jilin Sun, Margaret L. DeRose, Marina Stolina, David Chang, Gwyneth Y. Van, Kristie Clarkin, Hung Q. Nguyen, Yan Bin Yu, Shuqian Jing, Giorgio Senaldi, Gary Elliott, Eugene S. Medlock

Blood (2002) 100 (7): 2330–2340.

https://doi.org/10.1182/blood-2002-01-0012

Published: 2002

Journal Articles

Inflammatory Cytokines and Vascular Endothelial Growth Factor Stimulate the Release of Soluble Tie Receptor From Human Endothelial Cells Via Metalloprotease Activation

Rachel Yabkowitz, Susanne Meyer, Tabitha Black, Gary Elliott, Lee Anne Merewether, Harvey K. Yamane

Blood (1999) 93 (6): 1969–1979.

https://doi.org/10.1182/blood.V93.6.1969.406k14_1969_1979

Published: 1999

Journal Articles

Natural Killer and B-Lymphoid Potential in CD34 + Cells Derived From Embryonic Stem Cells Differentiated in the Presence of Vascular Endothelial Growth Factor

Naoki Nakayama, Inghwa Fang, Gary Elliott

Blood (1998) 91 (7): 2283–2295.

https://doi.org/10.1182/blood.V91.7.2283

Published: 1998

Journal Articles

Regulation of Tie Receptor Expression on Human Endothelial Cells by Protein Kinase C-Mediated Release of Soluble Tie

Rachel Yabkowitz, Susanne Meyer, Donna Yanagihara, David Brankow, Tabitha Staley, Gary Elliott, Sylvia Hu, Barry Ratzkin

Blood (1997) 90 (2): 706–715.

https://doi.org/10.1182/blood.V90.2.706

Published: 1997

NARROW

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Mechanism of Action and Safety of Second Generation Analogs of SDX-101 (R-Etodolac).

SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.

SDX-105 (Treanda™) Enhances the Tumor Growth Inhibitory Effect of Rituximab in Daudi Lymphoma Xenografts.

Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production

Inflammatory Cytokines and Vascular Endothelial Growth Factor Stimulate the Release of Soluble Tie Receptor From Human Endothelial Cells Via Metalloprotease Activation

Natural Killer and B-Lymphoid Potential in CD34 + Cells Derived From Embryonic Stem Cells Differentiated in the Presence of Vascular Endothelial Growth Factor

Regulation of Tie Receptor Expression on Human Endothelial Cells by Protein Kinase C-Mediated Release of Soluble Tie

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only